Clinical Research Directory
Browse clinical research sites, groups, and studies.
Naltrexone Neuroimaging in Teens With Eating Disorders
Sponsor: Children's Mercy Hospital Kansas City
Summary
Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).
Official title: Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
Key Details
Gender
All
Age Range
13 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-09-17
Completion Date
2027-06
Last Updated
2025-11-25
Healthy Volunteers
No
Conditions
Interventions
Naltrexone
Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
Placebo
Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
Locations (1)
Children's Mercy Research Institute
Kansas City, Missouri, United States